Page last updated: 2024-08-22

lutetium and Ache

lutetium has been researched along with Ache in 10 studies

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (10.00)18.2507
2000's2 (20.00)29.6817
2010's4 (40.00)24.3611
2020's3 (30.00)2.80

Authors

AuthorsStudies
Flux, G; Liepe, K; Murray, I1
Allen, JC; Kanesvaran, R; Lam, WWC; Ler, ASL; Ng, DCE; Somanesan, S; Tay, YS; Thang, SP; Tong, AKT; Wong, ASC1
Bakar, HE; Begec, T; Cayırlı, YB; Celen, YZ; Elboga, U; Eryilmaz, K; Kilbas, B; Mercanoglu, G; Sahin, E1
Bins, A; Braat, A; de Keizer, B; Hunting, J; Krijger, G; Lam, M; Mehra, N; van Kalmthout, L; van Leeuwaarde, R; Ververs, T1
Baum, RP; Meckel, M; Nauth, A; Puranik, AD; Rösch, F; Timpe, J; Zhernosekov, K1
Baum, RP; Klette, I; Kulkarni, HR; Mueller, D; Schottelius, M; Schuchardt, C; Singh, A; Wester, HJ; Wiessalla, S; Wirtz, M1
Abbasi, IA1
Banerjee, S; Chakraborty, S; Das, T; Pillai, MR; Samuel, G; Sarma, HD; Unni, PR; Venkatesh, M1
Banerjee, S; Chakraborty, S; Das, T; Sarma, HD; Venkatesh, M1
Ando, A; Ando, I; Fujita, N; Kataiwa, A; Kazuma, K; Kinuya, S; Nakagawa, M; Tonami, N1

Reviews

1 review(s) available for lutetium and Ache

ArticleYear
Dosimetry of Bone Seeking Beta Emitters for Bone Pain Palliation Metastases.
    Seminars in nuclear medicine, 2022, Volume: 52, Issue:2

    Topics: Bone and Bones; Bone Neoplasms; Humans; Lutetium; Pain; Radiopharmaceuticals; Rhenium; Tissue Distribution; Zoledronic Acid

2022

Trials

1 trial(s) available for lutetium and Ache

ArticleYear
Clinical outcomes of 177lutetium-prostate-specific membrane antigen therapy in advanced prostate cancer-a prospective pilot study in an Asian population.
    Nuclear medicine communications, 2020, Volume: 41, Issue:7

    Topics: Adult; Aged; Asian People; Humans; Kallikreins; Lutetium; Male; Middle Aged; Pain; Pilot Projects; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Survival Analysis; Treatment Outcome

2020

Other Studies

8 other study(ies) available for lutetium and Ache

ArticleYear
An automated synthesis of 177Lu-EDTMP as an efficient bone-seeking therapeutic radiopharmaceutical.
    European review for medical and pharmacological sciences, 2021, Volume: 25, Issue:14

    Topics: Aged; Automation; Bone Neoplasms; Female; Humans; Injections, Intravenous; Lutetium; Male; Molecular Structure; Organometallic Compounds; Pain; Pain Management; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals

2021
First Experience With 177Lu-PSMA-617 Therapy for Advanced Prostate Cancer in the Netherlands.
    Clinical nuclear medicine, 2019, Volume: 44, Issue:6

    Topics: Aged; Aged, 80 and over; Analgesics; Antineoplastic Agents; Dipeptides; Fatigue; Follow-Up Studies; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Netherlands; Pain; Pain Measurement; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome; Xerostomia

2019
Development of a [177Lu]BPAMD labeling kit and an automated synthesis module for routine bone targeted endoradiotherapy.
    Cancer biotherapy & radiopharmaceuticals, 2015, Volume: 30, Issue:2

    Topics: Aged; Amides; Bone and Bones; Bone Neoplasms; Diphosphonates; Humans; Lutetium; Male; Pain; Radioisotopes; Radiopharmaceuticals; Reagent Kits, Diagnostic; Staining and Labeling

2015
177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2016, Volume: 57, Issue:7

    Topics: Aged; Antigens, Surface; Cohort Studies; Dipeptides; Disease-Free Survival; Edetic Acid; Erythrocyte Count; Gallium Isotopes; Gallium Radioisotopes; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Leukocyte Count; Lutetium; Male; Neoplasm Metastasis; Oligopeptides; Organometallic Compounds; Pain; Patient Selection; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiometry; Radiopharmaceuticals; Treatment Outcome

2016
Studies on 177Lu-labeled methylene diphosphonate as potential bone-seeking radiopharmaceutical for bone pain palliation.
    Nuclear medicine and biology, 2011, Volume: 38, Issue:3

    Topics: Animals; Bone and Bones; Diphosphonates; Feasibility Studies; Hydrogen-Ion Concentration; Lutetium; Male; Pain; Pain Management; Palliative Care; Quality Control; Radiochemistry; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Temperature; Time Factors

2011
177Lu-labeled cyclic polyaminophosphonates as potential agents for bone pain palliation.
    Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, 2002, Volume: 57, Issue:2

    Topics: Animals; Bone Neoplasms; Heterocyclic Compounds, 1-Ring; Lutetium; Organophosphonates; Organophosphorus Compounds; Pain; Palliative Care; Radioisotopes; Radiopharmaceuticals; Rats; Rats, Wistar; Tissue Distribution

2002
Comparative studies of 177Lu-EDTMP and 177Lu-DOTMP as potential agents for palliative radiotherapy of bone metastasis.
    Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, 2008, Volume: 66, Issue:9

    Topics: Animals; Bone Neoplasms; Drug Stability; Lutetium; Organometallic Compounds; Organophosphorus Compounds; Pain; Palliative Care; Rabbits; Radioisotopes; Rats; Rats, Wistar; Tissue Distribution

2008
177Lu-EDTMP: a potential therapeutic bone agent.
    Nuclear medicine communications, 1998, Volume: 19, Issue:6

    Topics: Animals; Beta Particles; Bone and Bones; Bone Neoplasms; Femur; Gamma Rays; Humans; Lutetium; Male; Organometallic Compounds; Organophosphorus Compounds; Pain; Palliative Care; Radiopharmaceuticals; Rats; Rats, Wistar; Technetium Tc 99m Medronate; Time Factors; Tissue Distribution

1998